PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC)

被引：0
|
作者：
Tannir, Nizar M.
Agarwal, Neeraj
Pal, Sumanta K.
Cho, Daniel C.
Formiga, Maria
Guo, Jun
George, Daniel J.
Tagliaferri, Mary Ann
Singel, Stina Mui
O'Keeffe, Bridget A.
Hannah, Alison L.
Balbas, Minna
Penkov, Konstantin
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] NYU, Perlmutter Canc Ctr, Langone Hlth, New York, NY USA
[5] AC Camargo Canc Ctr, Sao Paulo, Brazil
[6] Peking Univ, Canc Hosp & Inst, Beijing Shi, Peoples R China
[7] Duke Univ, Sch Med, Durham, NC USA
[8] Nektar Therapeut, San Francisco, CA USA
[9] Private Med Inst Euromedserv, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS763
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.
    Choueiri, Toni K.
    Albiges, Laurence
    Powles, Thomas
    Scheffold, Christian
    Wang, Fong
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL).
    Dreyling, martin H.
    Tam, Constantine Si Lun
    Wang, Michael
    Smith, Stephen Douglas
    Ladetto, Marco
    Huang, Huiqiang
    Elstrom, Rebecca L.
    Co, Melannie
    Holmgren, Eric
    Huang, Jane
    Gouill, Steven Le
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.
    Pal, Sumanta K.
    Albiges, Laurence
    Rodriguez, Cristina Suarez
    Liu, Bo
    Doss, Jennifer
    Khurana, Sudha
    Scheffold, Christian
    Voss, Martin H.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
    Ahrens, Marit
    Escudier, Bernard
    Boleti, Ekaterini
    Grimm, Marc-Oliver
    Gross-Goupil, Marine
    Barthelemy, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast)
    Ahrens, Marit
    Escudier, Bernard
    Boleti, Ekaterini
    Grimm, Marc-Oliver
    Goupir, Marine Gross
    Barthelemy, Pilippe
    Gravis, Gwenaelle
    Bedekes, Jens
    Ivanyi, Philipp
    Panic, Andrej
    Zschaebitz, Stefanie
    Neyrieru, Sylvie
    Mellado, Begona
    Biel, Anika
    Wadell, Tom
    Pablo Maroto, Jose
    Retz, Margitta
    Boegemann, Martin
    Rottey, Sylvie
    Haanen, John
    Oosting, Sjoukje
    Castellano, Daniel
    Hartmann, Arndt
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 226 - 226
  • [36] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
    Ahrens, Marit
    Escudier, Bernard
    Haanen, John B. A. G.
    Boleti, Ekaterini
    Goupil, Marine Gross
    Grimm, Marc-Oliver
    Negrier, Sylvie
    Barthelemy, Philippe
    Gravis, Gwenaelle
    Ivanyi, Philipp
    Bedke, Jens
    Castellano, Daniel
    Panic, Andrej
    Mellado, Begona
    Maroto-Rey, Pablo
    Rottey, Sylvie
    Zschaebitz, Stefanie
    Deckbar, Dorothee
    Hartmann, Arndt
    Bergmann, Lothar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Burotto, Mauricio
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 63 - 71
  • [38] A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non- clear cell renal cell carcinoma (SUNIFORECAST)
    Bergmann, L.
    Grimm, M. O.
    Boleti, E. B.
    Panic, A.
    Gruellich, C.
    Bedke, J.
    Ahrens, M.
    Lorch, A.
    Negrier, S.
    Ravaud, A.
    Retz, M.
    Boegemann, M.
    Ivanyi, P.
    Siemer, S.
    Bathelemy, P.
    Rottey, S.
    Maroto, P.
    Oosting, S.
    Hartmann, A.
    Escudier, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 285 - 285
  • [39] An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)
    Ahrens, Marit
    Escudier, Bernard
    Haanen, John
    Boleti, Ekaterini
    Gross-Goupil, Marine
    Grimm, Marc-Oliver
    Negrier, Sylvie
    Barthelemy, Philippe
    Gravis, Gwenaelle
    Ivanyi, Philipp
    Bedke, Jens
    Castellano, Daniel
    Panic, Andrej
    Mellado, Begona
    Maroto, Pablo
    Rottey, Sylvie
    Zschaebitz, Stefanie
    Floercken, Anne
    Boegemann, Martin
    Waddell, Tom
    Rodriguez, Cristina Suarez
    Lorch, Anja
    Deckbar, Dorothee
    Hartmann, Arndt
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 101 - 102
  • [40] An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)
    Ahrens, M.
    Escudier, B.
    Haanen, J. B. A. G.
    Boleti, E.
    Goupil, Gross M.
    Grimm, M. O.
    Negrier, S.
    Barthelemy, P.
    Gravis, G.
    Ivany, P.
    Bedke, J.
    Castellano, D.
    Panic, A.
    Mellado, B.
    Maroto, J. P.
    Roten, S.
    Zschaebitz, S.
    Deckbar, D.
    Hartmann, A.
    Bergmann, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 74 - 75
12345